High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023
The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already...
Subscriber login:
SUBMIT
Remember me
Search
- Jul 21
California Initiative Provides $100 Million to Produce Its Own Insulin Biosimilars
The budget allocates half of the money for the development of low-cost interchangeable insulin biosimilars and the other half for...
- Jul 16
Biogen/ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
ICER's expert group unanimously voted against Biogen's Aduhelm and its benefit for Alzheimer's patients. (Biogen) By Noah Higgins-Dunn |...
- Jun 22
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...
- Jun 1
6 Payor Tactics to Control Drug Spending
By Karen Blum The growth of high-cost specialty drugs is causing payors to scramble to manage spending on these products, speakers said...
- Jun 1
Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...
- May 30
New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says
With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...
- May 26
Payer Management Tools and Trends for Biosimilars in the US
As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...
- Apr 12
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...
- Apr 1
Upcoming Generics Provide New Considerations and Opportunities for Savings
In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...
- Mar 29
Jeffery Casberg Previews His Presentations at AMCP 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products...
- Mar 25
Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022
The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty...
- Dec 24, 2021
Paths to Approval: Understanding U.S. Regulatory Pathways for Drug Products
This article details the potential regulatory approval pathways.
- Dec 23, 2021
Potential Market Exclusivity Granted During U.S. Regulatory Approval Process
This article explains potential data and market exclusivity granted during the U.S. regulatory approval process.
- Dec 22, 2021
Understanding the Process for FDA Approval and Expedited Review
This article details the FDA evaluation process and expedited review designations.
- Dec 16, 2021
Medical Drug Coding And Reimbursement 101
This article explains medical drug coding and reimbursement.
- Dec 15, 2021
Drug Pricing Part 2: Generic Drug Pricing
This article explains generic drug pricing, associated terms, including MAC rates and lists, biosimilar pricing, and more.
- Dec 14, 2021
Drug Pricing Part 1: Key Terms, Stakeholders, and Brand Drug Pricing Processes
This article answers the question, "how does branded drug pricing work?" defining associated terms such as average wholesale price, wholesal
- Nov 18, 2021
How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options
An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.
- Nov 1, 2021
IPD Executive Offers Perspective on Biosimilar Uptake and Policy
Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.
- Nov 1, 2021
Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve
Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.
- Oct 27, 2021
An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
Competitors in the field of adalimumab and insulin products may soon include authorized biologics.
- Oct 22, 2021
AMCP Nexus 2021: A Wrap-Up
Biosimilar adoption and biosimilar market share were among the featured topics at the AMCP Nexus 2021 meeting in Denver, Colorado.
- Oct 21, 2021
AMCP Nexus 2021: Biosimilars Are Gathering Momentum — and Interchangeability May Not Matter
IPD Analytics discussed biosimilar uptake as both biosimilar market share and adoption of biosimilars become more prominent.